Regulatory Bayer’s asundexian starts EU review for ischaemic stroke PharmaphorumThe EMA has started its review of Bayer's asundexian for secondary stroke prevention, keeping it ahead of a rival drug from BMS and J J.CardiovascularRead full story pharminent June 10, 2026 (Last updated: June 10, 2026) Pharmaphorum The EMA has started its review of Bayer’s asundexian for secondary stroke prevention, keeping it ahead of a rival drug from BMS and J J. Cardiovascular Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: AbbVie’s migraine drug cleared for migraine attacks on NHSNext: Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug Related Stories Regulatory Viridian wins FDA approval for Lumvoa for thyroid eye disease pharminent June 29, 2026 Regulatory Lilly’s Jaypirca receives CHMP positive opinion for CLL in Europe pharminent June 29, 2026 Regulatory Replimune gets early August decision date for twice-rejected melanoma drug pharminent June 26, 2026
